- Coordinator
- Ankara Universitesi, Türkiye
- Runs
- 1 September 2026 to 31 August 2030
- Status
- Running
- EU funding
- €1.8m
- Total cost
- —
- Partners
- 23 organisations in 15 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101299913
What the project is doing
In the project's own words, from its summary on CORDIS.
OMNIA is a European-led, globally connected research and training programme redefining how nanotherapeutics are designed and translated for hard-to-treat cancers. By integrating spatial multi-omics, advanced tumor models, and interpretable AI, OMNIA uncovers how nanoparticles interact with the tumor microenvironment—turning complex molecular data into actionable design rules for safer, more effective treatments. Through a harmonized nanoparticle platform, standardized SOPs, and FAIR-compliant data pipelines, OMNIA transforms fragmented nanomedicine studies into a reproducible, data-driven field.
Its consortium of leading academic, clinical, and industrial partners from Europe, North America, and Asia bridges expertise in materials science, oncology, and AI to deliver open spatial atlases, validated analysis tools, and regulatory-ready templates. At its core, OMNIA is also a training ecosystem. Over 80 researchers will engage in structured, cross-sector secondments—“capsule curricula” that combine hands-on experimentation, AI analysis, and translational science.
This approach cultivates a new generation of scientists fluent in materials–biology–AI integration and capable of driving Europe’s next wave of cancer nanomedicine. Organized into five interconnected work packages spanning nanoparticle design, characterization, spatial biology, AI, and ethics, OMNIA combines scientific excellence, industrial innovation, and mobility-driven collaboration—laying the foundation for a sustainable, spatially informed, AI-enabled future in nanomedicine.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Ankara Universitesi | Tandogan Ankara | Türkiye | Coordinator |
| Khalifa University of Science and Technology | Abu Dhabi | AE | Associatedpartner |
| Yoursciencebe | Bruxelles / Brussel | Belgium | Participant |
| The University of Manitoba | Manitoba | Canada | Associatedpartner |
| Fundacio Institut Catala De Nanociencia I Nanotecnologia | Bellaterra (Barcelona) | Spain | Participant |
| Turun Yliopisto | Turku | Finland | Participant |
| Centre De Lutte Contre Le Cancer Leon Berard | Lyon | France | Participant |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Associatedpartner |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Associatedpartner |
| Universite Lyon 1 Claude Bernard | Villeurbanne Cedex | France | Associatedpartner |
| Universita Degli Studi Di Padova | Padova | Italy | Participant |
| Universita Degli Studi Di Sassari | Sassari | Italy | Participant |
| Pusan National University | Busan | South Korea | Associatedpartner |
| Latvijas Universitate | Riga | Latvia | Participant |
| Uniwersytet Im. Adama Mickiewicza Wpoznaniu | Poznan | Poland | Participant |
| Bluepharma - Industria Farmaceuticasa | Coimbra | Portugal | Participant |
| Universidade De Coimbra | Coimbra | Portugal | Participant |
| Csd Health Care | Kyiv | Ukraine | Participant |
| Materials Research Center | Kiev | Ukraine | Participant |
| The University of Birmingham | Birmingham | United Kingdom | Participant |
| Augusta University Research Institute, Inc. | Augusta | United States | Associatedpartner |
| Drexel University | Philadelphia | United States | Associatedpartner |
| University of Miami | Coral Gables Miami | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI